Sector News

Brazil's Odebrecht mulls selling part of stake in Braskem -report

February 16, 2018
Energy & Chemical Value Chain

Brazilian conglomerate Odebrecht SA may sell part of its stake in petrochemical company Braskem SA or try to get credit from banks using its stake as collateral, Brazilian newspaper Valor Economico reported on Wednesday.

Odebrecht needs cash to pay debt maturing this year, including 500 million reais ($152 million) in bonds, according to the paper, which cited unnamed sources.

In a statement, the group said it “is constantly talking to its creditor banks,” but did not confirm any new transactions.

Part of the Braskem stake is already pledged in collateral to banks, and all dividends have also been surrendered to service the debt, Reuters reported last year.

Odebrecht has around 75 billion reais ($23 billion) in outstanding debt.

($1 = 3.2947 reais)

By Tatiana Bautzer and Alexandra Alper

Source: Reuters

comments closed

Related News

February 7, 2025

Air Products appoints Eduardo F. Menezes CEO

Energy & Chemical Value Chain

Air Products recently announced the appointment of Eduardo F. Menezes as Chief Executive Officer (CEO) of Air Products effective February 7, 2025, succeeding Seifollah (“Seifi”) Ghasemi, who is leaving the Company after more than 10 years of dedicated service.

February 7, 2025

Blastr Green Steel completes partner financing round for ultra-low CO2 steel value chain

Energy & Chemical Value Chain

Blastr Green Steel (Blastr) has successfully completed a second strategic partner financing round, advancing the development of a European integrated ultra-low CO2 steel value chain with its flagship steel plant in Finland. The partner financing round included three of Blastr’s founding investors and three new investors based in Finland, all with a common emphasis on sustainable growth.

February 7, 2025

Mitsubishi Chemical sells Mitsubishi Tanabe Pharma to Bain Capital for $3.3B

Energy & Chemical Value Chain

Mitsubishi Chemical Group has signed an agreement to sell its pharmaceutical business Mitsubishi Tanabe Pharma Corp. to Bain Capital (Boston, Massachusetts). The cost of the transaction is ¥510 billion ($3.3 billion). The closing of this transaction is scheduled for the second quarter of 2026, subject to a resolution at the annual shareholders’ meeting scheduled in June 2025.

How can we help you?

We're easy to reach